Free Trial

Vaxcyte (NASDAQ:PCVX) Receives "Overweight" Rating from Cantor Fitzgerald

Vaxcyte logo with Medical background

Cantor Fitzgerald reaffirmed their overweight rating on shares of Vaxcyte (NASDAQ:PCVX - Free Report) in a report published on Thursday morning, Benzinga reports.

Separately, Needham & Company LLC restated a buy rating and set a $95.00 target price on shares of Vaxcyte in a research note on Thursday, May 9th.

Get Our Latest Report on Vaxcyte

Vaxcyte Trading Up 0.7 %

Shares of PCVX traded up $0.51 during trading hours on Thursday, hitting $72.76. The company had a trading volume of 561,036 shares, compared to its average volume of 751,226. The company has a market capitalization of $7.92 billion, a PE ratio of -17.00 and a beta of 0.97. Vaxcyte has a one year low of $44.20 and a one year high of $82.04. The company's fifty day moving average price is $67.75 and its two-hundred day moving average price is $67.00.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.28. Analysts forecast that Vaxcyte will post -3.96 earnings per share for the current year.


Insider Buying and Selling

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the transaction, the chief financial officer now directly owns 95,679 shares in the company, valued at approximately $5,862,252.33. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business's stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $61.92, for a total transaction of $928,800.00. Following the sale, the chief executive officer now owns 477,847 shares in the company, valued at approximately $29,588,286.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $61.27, for a total value of $490,160.00. Following the sale, the chief financial officer now owns 95,679 shares in the company, valued at approximately $5,862,252.33. The disclosure for this sale can be found here. Insiders have sold a total of 86,483 shares of company stock worth $5,917,483 in the last ninety days. 3.10% of the stock is owned by insiders.

Institutional Trading of Vaxcyte

Several large investors have recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Vaxcyte by 16.6% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 25,059 shares of the company's stock worth $1,712,000 after buying an additional 3,564 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Vaxcyte by 11,000.0% in the first quarter. Farallon Capital Management LLC now owns 377,400 shares of the company's stock worth $25,780,000 after buying an additional 374,000 shares during the last quarter. RA Capital Management L.P. boosted its stake in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company's stock worth $560,398,000 after buying an additional 312,500 shares during the last quarter. Tidal Investments LLC acquired a new position in Vaxcyte in the 1st quarter worth about $405,000. Finally, California State Teachers Retirement System raised its holdings in Vaxcyte by 11.8% in the 1st quarter. California State Teachers Retirement System now owns 92,026 shares of the company's stock worth $6,286,000 after purchasing an additional 9,695 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Recommended Stories

Should you invest $1,000 in Vaxcyte right now?

Before you consider Vaxcyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.

While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Top Market Leaders Splitting Their Stocks
How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines